Relmada Therapeutics
215 articles about Relmada Therapeutics
-
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
3/19/2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023.
-
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
3/12/2024
Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.
-
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
3/5/2024
Relmada Therapeutics, Inc. today announced that they will participate in the Leerink Partners Global Biopharma Conference.
-
Relmada Therapeutics Provides Corporate Update
1/4/2024
Relmada Therapeutics, Inc. today provided a corporate update, highlighted the Company's key 2023 accomplishments and outlined its anticipated 2024 clinical development milestones.
-
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/8/2023
Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023.
-
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
11/3/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023.
-
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
10/11/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023, being held November 10-14, 2023, in Boston, MA.
-
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
10/9/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD) today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in one-on-one investor meetings and a fireside chat on Thursday, October 12, 2023, at 2:30pm ET in New York, NY.
-
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
10/6/2023
Relmada Therapeutics, Inc. today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
-
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
9/20/2023
Relmada Therapeutics, Inc. today announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3, long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
-
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
8/23/2023
Relmada Therapeutics, Inc. today announced the dosing of the first patient in the Relight (study 304) Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of Major Depressive Disorder (MDD).
-
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8/8/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the second quarter ended June 30, 2023.
-
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
8/1/2023
Relmada Therapeutics, Inc. today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023.
-
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
6/8/2023
Relmada Therapeutics, Inc. today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Goldman Sachs Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Wednesday, June 14, 2023, at 3:20pm PT / 6:20pm ET in Dana Point, CA.
-
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
6/2/2023
Relmada Therapeutics, Inc. today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY.
-
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
5/24/2023
Relmada Therapeutics, Inc. today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting.
-
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
5/11/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.
-
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
5/8/2023
Relmada Therapeutics, Inc. today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11th, 2023.
-
Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder.
-
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
3/23/2023
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022.